Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 46,264 shares of the company's stock, valued at approximately $2,477,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.09% of Janux Therapeutics at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of JANX. Russell Investments Group Ltd. grew its holdings in Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after purchasing an additional 442 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Janux Therapeutics in the fourth quarter worth about $59,000. Meeder Asset Management Inc. bought a new position in shares of Janux Therapeutics in the fourth quarter worth about $159,000. Tower Research Capital LLC TRC boosted its stake in shares of Janux Therapeutics by 878.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company's stock worth $205,000 after acquiring an additional 3,436 shares during the period. Finally, Brevan Howard Capital Management LP bought a new position in shares of Janux Therapeutics in the fourth quarter worth about $221,000. Institutional investors own 75.39% of the company's stock.
Insider Transactions at Janux Therapeutics
In related news, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the transaction, the insider now owns 82,139 shares of the company's stock, valued at $2,630,912.17. This represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 8.10% of the company's stock.
Analysts Set New Price Targets
A number of research firms have recently weighed in on JANX. Wedbush reaffirmed an "outperform" rating and issued a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Scotiabank decreased their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Janux Therapeutics presently has an average rating of "Buy" and an average price target of $95.25.
View Our Latest Research Report on Janux Therapeutics
Janux Therapeutics Stock Performance
JANX stock traded up $1.45 during midday trading on Friday, reaching $26.21. 609,347 shares of the company traded hands, compared to its average volume of 868,305. Janux Therapeutics, Inc. has a 52-week low of $22.48 and a 52-week high of $71.71. The business has a 50 day moving average of $27.04 and a 200-day moving average of $37.83. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -22.40 and a beta of 2.96.
Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.
About Janux Therapeutics
(
Free Report)
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
See Also
Before you consider Janux Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.
While Janux Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
